Aspirin twice a day keeps new COX-1 at bay

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1217-1219

  Lordkipanidze M ^a   Harrison, P ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; THROMBOXANE B2;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC PATIENT; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA;

ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE;

EID: 84863456153     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04764.x     Document Type: Note

References (25)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-701.
3. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35: S11-63.
4. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012; doi: 10.1155/2012/376721.
5. Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol Ther 2006; 112: 733-43.
6. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005; 57(Suppl.): 42-58.
7. Davi G, Vazzana N, Sestili S. Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins Other Lipid Mediat 2012; doi:.
8. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-8.
9. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Bal Dit Sollier C, Drouet L. 24-hour time dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2010; 105: 336-44.
10. Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011; 150: 39-44.
11. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davi G, Patrono C, Rocca B. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-61.
12. Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc Dis 2011; 21: 542-5.
13. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-603.
14. Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia. Thromb Res 2012; 129: 91-4.
15. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-6.
16. Di Minno MN, Lupoli R, Palmieri NM, Russolillo A, Buonauro A, Di Minno G. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res 2012; 129: 341-4.
17. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davi G, Patrono C. The recovery of platelet cyclooxygenase activity explains interindividual variability of responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-30.
18. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
19. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-84.
20. Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
21. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-7.
22. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106: 491-9.
23. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-91.
24. Harrison P, Goodall AH. 'Message in the platelet'- more than just vestigial mRNA!. Platelets 2008; 19: 395-404.
25. ISRCTN register. Impact of single versus double dose acetylsalicylic acid on platelet function in patients with type 2 diabetes: a randomised crossover study. Available from Accessed on 2 March 2012.